TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Health center nurse knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community health worker knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health center nurse clinical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidermal Nerve Density Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: concentration of ALX-0171 in BALF samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of ALX-0171 in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of ALX-0171 in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing of Subsequent Births
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Child Maltreatment Reports
Endpoint domain: Adverse events/effects
Primary endpoint: Arrests
Endpoint domain: Adverse events/effects
Primary endpoint: Total Pre-op IV Morphine Equivalents (TIVME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of quadriceps muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Autonomic nervous system response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evoked Potential response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum serotonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Patients With Donor Cell Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Talar Tilt Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anterior Drawer Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: American Orthopaedic Foot and Ankle Society
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bronchodilatory efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Stage of Prolapse of the Anterior Vaginal Wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Anxiety Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PTSD Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Rise From a Chair 10 Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of definitive indirect crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concordance Rate in Stated Goals of Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment satisfaction with ICD therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Lamotrigine Concentration vs. Time Curve (AUC 0-Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Signal Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Single-item Self-Esteem Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Desire for Social Interaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Postpartum body weight regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MTX-PG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD38+ CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forceplate Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ventilation/ perfusion ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial gas measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical progression of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression--Improvement score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Affective Reactivity Index (ARI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early morbidity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Plasma Oxalate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensation rating of urgency to defecate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensation threshold for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Airborne nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bleeding score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Log viral load change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in faecal bacterial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of asymmetrical cerebral desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of SAHA in combination with bortezomib
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Number of Participants with Immune-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Red Blood Cell (RBC):Barrier Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of pre- & malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cmax - the maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - the area under the plasma concentration-time curve from time zero to the last sampling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hospital-acquired infection
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Anti-MCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of fasting plasma acyl ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: correlation coefficient between serum level of osteoponton and vascular affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total Self-Efficacy Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Malaria infection at the time of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fetal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory effect of clopidogrel on platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in clinical score for OLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality during acute hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Duration of organ failure support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sperm count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of spinal anesthesia induced hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of the first period of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of Patient Participants with Under-Recognized Major Depressive Disorder (MDD) Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAS peptide concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barratt Simplified Measure of Social Status
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Coping Orientation to Problems Experienced
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Multidimensional Scale of Perceived Social Support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: HDL Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upper reference limit of high-sensitivity troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Teacher-Child Interaction Coding System (TCICS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Hives Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinical clearance rate (CCR) of treated actinic keratosis lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dopamine Transporter Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Toxicities as assessed by NCI CTCAE version 3
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility as evaluated by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI brain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lupus-related Appointment Nonadherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite Measure of Acute Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of Lupus Care: SLE Quality Metric Scoring System for Adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 11C-PK11195 binding in MS patient brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 11C-SMW139 binding in MS patient brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: QSM-signal in MS patient brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Responders on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with moderate to severe hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of subjects with SARS-CoV-2 positive serology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Purchase Behaviours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Liver fat %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: objective structured clinical examination (OSCE) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device related adverse valve events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Died by Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of repetitive and stereotypical behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of TH-302
Endpoint domain: Adverse events/effects
Primary endpoint: dose-limiting toxicity of TH-302
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (Complete Response Rate and Partial Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Internal motion measurement during ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: clinical improvement in Atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of NK cell doses
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of sensory oxaliplatin-induced peripheral neuropathy response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chronic neuropathic pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with Adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity as assessed by HAI antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in Square-Root Transformed GA Area Expansion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of cytological conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hypoxia-related gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of quadriceps and abdominal muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Experiencing a Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Microbial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pathogens identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Rated Successful at Performing Specific Tasks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in 24 h average SBP and DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Respiratory Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of 3D-RWC-TVS in diagnosing rectosigmoid endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of vaccine-related Grade 2 or greater local or systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of vaccine-related Grade 2 or greater local or systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Natural history of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Surgical Bed-Recurrence Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Use of communication platform
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in Lung Function - Increase in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease Stabilization - Decrease in FEV1 or Less Than 10% Increase in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease Progression - Decrease in FEV1 or Additional/Increase in Immunosuppressive Therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Interferon epsilon expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline naso-pharyngeal viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diameter of the Pupil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated Haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: immunological response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: midazolam AUC ratio (treatment/control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest CT-scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent binary restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: FFNP Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: p53 target gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of endplate degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of intervertebral disc degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migration of femoral component into the bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periprosthetic femoral bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total ocular symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Activities Specific Balance Confidence Scale (ABC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Mini Balance Evaluation Systems Test (MiniBEST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Mobility life space scale (MLSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary Technical Success Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of total scores of Social Responsiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes of total scores of Repetitive Behavior Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of PEP02
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of deaths until Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Genitourinary toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Brace wearing frequency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number and Severity of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous and elicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cortisol (24-hour urine. AM plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intraocular pressure (IOP) assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Deviation from optimal ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Consistency of optimal ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: cumulative hierarchical incidence of MACE
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and Specificity of the abioSCOPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived hydration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status